Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 675,993
  • Shares Outstanding, K 54,692
  • Annual Sales, $ 227,190 K
  • Annual Income, $ 115,550 K
  • 60-Month Beta 0.50
  • Price/Sales 3.00
  • Price/Cash Flow 5.77
  • Price/Book 1.55
Trade VNDA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.10
  • Number of Estimates 1
  • High Estimate 0.10
  • Low Estimate 0.10
  • Prior Year 0.08
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.07 +21.15%
on 10/28/20
13.46 -9.36%
on 11/16/20
+1.95 (+19.02%)
since 10/23/20
3-Month
9.00 +35.56%
on 09/25/20
13.46 -9.36%
on 11/16/20
+1.54 (+14.45%)
since 08/21/20
52-Week
7.12 +71.35%
on 03/18/20
17.85 -31.65%
on 12/09/19
-4.04 (-24.88%)
since 11/22/19

Most Recent Stories

More News
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

MRK : 79.56 (-1.11%)
BMY : 61.26 (-0.57%)
HALO : 40.00 (+1.39%)
VNDA : 12.15 (-1.70%)
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion

Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.

REGN : 521.64 (+0.56%)
RHHBY : 41.1800 (-1.20%)
VNDA : 12.15 (-1.70%)
CARA : 15.02 (-2.02%)
Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 12.15 (-1.70%)
Vanda: 3Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported third-quarter net income of $5.9 million.

VNDA : 12.15 (-1.70%)
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended .

VNDA : 12.15 (-1.70%)
Vanda Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 28, 2020 / Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 28, 2020...

VNDA : 12.15 (-1.70%)
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate...

VNDA : 12.15 (-1.70%)
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on , after the market closes.  

VNDA : 12.15 (-1.70%)
Spectrum Brands Holdings Appoints Gautam Patel and Anne S. Ward to the Board of Directors

Spectrum Brands Holdings, Inc. (NYSE: SPB; "Spectrum Brands" or the "Company"), a leading global branded consumer products and home essentials company focused on driving innovation and providing exceptional...

SPB : 66.67 (+2.41%)
AMRX : 4.09 (-0.49%)
VNDA : 12.15 (-1.70%)
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the...

VNDA : 12.15 (-1.70%)
SUPN : 20.65 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 12.66
1st Resistance Point 12.51
Last Price 12.15
1st Support Level 12.20
2nd Support Level 12.05

See More

52-Week High 17.85
Fibonacci 61.8% 13.75
Fibonacci 50% 12.49
Last Price 12.15
Fibonacci 38.2% 11.22
52-Week Low 7.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar